Stalicla Secures CHF 2 Million Financing from Addex Therapeutics
STALICLA SA, a clinical-stage biotech firm specializing in precision medicine for neurodevelopmental and neuropsychiatric disorders, has successfully finalized a CHF 2 million financing led by Addex Therapeutics. This significant funding is aimed at advancing operations and program development in neurodevelopmental disorders. It demonstrates strong investor confidence in Stalicla's innovative DEPI precision neuro platform, as well as its impressive portfolio of precision autism assets, notably STP1 and STP2.
Accelerating Development with Strategic Funding
The recent financing effort will undoubtedly propel Stalicla towards key milestones as it prepares for an upcoming Series C financing round, along with forming strategic partnerships for essential programs. Stalicla's focus is not just on immediate gains; they are actively working to enhance treatments and initiate critical clinical trials, specifically targeting autism and substance use disorders.
Innovative Assets Leading the Charge
One of the standout programs within the pipeline is STP7, derived from mavoglurant, which is touted as the most advanced mGluR5 negative allosteric modulator. This program has already wrapped up a Phase 3 enabling drug-drug interaction study. The company expects the Phase 3 development to be supported by the National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) through a Collaborative Research and Development Agreement.
Leadership Changes to Foster Growth
In conjunction with the recent financing, Tim Dyer has taken up the role of Chairman on the Board of Directors at Stalicla. Dyer, who also serves as the CEO of Addex, is optimistic about the firm's trajectory.
Strong Support for Innovative Medicine
"This financing is pivotal in extending our operational period to achieve vital milestones including the Series C financing," expressed Lynn Durham, CEO of Stalicla. "The support from the Addex-led syndicate is vital for the advancement of our precision medicine concepts, guiding us towards transformative clinical trials for autism and substance use disorders."
About STALICLA: Pioneers of Precision Medicine
STALICLA SA has positioned itself at the forefront of developing novel treatment options for neurodevelopmental disorders. With over $50 million raised in equity and an additional $30 million secured through non-dilutive funding, their goal is to radically improve the treatment landscape for neurodevelopmental disorders. They possess a validated neuro precision development platform capable of forming targeted patient subgroups, thus aiding in personalizing treatment avenues.
Investing in Future Trials
Currently, Stalicla is on the verge of initiating Phase 2 clinical trials for its foremost neurodevelopmental disorder asset, STP1, alongside another asset targeted at distinct autism populations. Rich in potential, STP7 (Mavoglurant) is also heading into Phase 3 trials, fully financed by the U.S. government, showcasing the confidence in Stalicla's innovative capabilities and commitment to advancing public health.
Looking Ahead: The Stalicla Vision
The vision Trailed by Stalicla's leadership focuses on transforming lives through innovative precision medicine strategies. Building on their advancements in targeting specific subpopulations within autism, Stalicla embodies a balanced approach towards ensuring both efficacy and accessibility in neurodevelopmental disorder treatments. The company remains unwavering in its mission, ready to tackle some of the most pressing challenges within the field of neurodevelopmental and neuropsychiatric disorders.
Frequently Asked Questions
1. What is the core focus of Stalicla's operations?
Stalicla specializes in precision medicine aimed at treating neurodevelopmental and neuropsychiatric disorders.
2. How much funding has Stalicla recently secured?
Stalicla secured CHF 2 million in financing led by Addex Therapeutics.
3. Who is now leading Stalicla's Board of Directors?
Tim Dyer has been appointed as the Chairman of the Board of Directors.
4. What are some key drugs in Stalicla's pipeline?
Key assets include STP1, STP2, and STP7 (mavoglurant) targeted towards neurodevelopmental disorders.
5. What trials is Stalicla looking to initiate soon?
Stalicla is preparing to start Phase 2 trials for STP1 and is also progressing STP7 to Phase 3.
